Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Launched by UNIVERSITY OF CHICAGO · Jan 25, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying Hidradenitis Suppurativa (HS), a skin condition that causes painful lumps and sores. The researchers want to find out if there are genetic links or traits that connect people with HS to their family members. By understanding these connections, the hope is to discover the cause of HS and potentially find better treatments for it.
If you or someone in your family has HS and is between the ages of 25 and 56, you might be eligible to participate. The study is looking for both individuals with HS and their family members who do not have the condition. Unfortunately, children under 7 years old cannot take part. If you join the study, you can expect to share information about your health and family history, which could help researchers learn more about HS. This is an important step towards improving care and treatment options for everyone affected by this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants (affected) with Hidradenitis Suppurativa and related symptoms
- • Family (unaffected) of participants with Hidradenitis Suppurativa
- Exclusion Criteria:
- • Children under 7-years of age
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Peter Nagele, MD, MSc
Principal Investigator
University of Chicago Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials